Alex Thompson CFA
Stock Analyst at Stifel Nicolaus
(4.96)
# 96
Out of 5,010 analysts
266
Total ratings
66.8%
Success rate
43.8%
Average return
Main Sectors:
Stocks Rated by Alex Thompson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Reiterated: Buy | $68 | $33.51 | +102.92% | 8 | Sep 23, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $132 → $152 | $122.06 | +24.53% | 12 | Sep 22, 2026 | |
| ROIV Roivant Sciences | Initiated Coverage: Buy | $51 | $38.22 | +33.44% | 1 | Sep 17, 2026 | |
| EVMN Evommune | Reiterated: Buy | $30 | $9.60 | +212.50% | 4 | Sep 9, 2026 | |
| ANAB AnaptysBio | Rated: Hold | n/a | $53.92 | - | 12 | Sep 8, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $328 → $326 | $237.57 | +37.22% | 17 | Sep 1, 2026 | |
| SEPN Septerna | Reiterated: Buy | $49 → $46 | $40.38 | +13.92% | 3 | Aug 16, 2026 | |
| ALMS Alumis | Reiterated: Buy | $44 | $8.11 | +442.54% | 6 | Aug 13, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $28 | $21.67 | +29.21% | 7 | Aug 13, 2026 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | $133 | $98.35 | +35.23% | 13 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $16.76 | +138.66% | 3 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $123 | $91.97 | +33.74% | 20 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $22.12 | +80.83% | 19 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 → $57 | $37.29 | +52.86% | 17 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $62 | $60.28 | +2.85% | 31 | Aug 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,255 → $1,282 | $963.79 | +33.02% | 30 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.69 | +195.86% | 4 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 | $94.55 | +58.65% | 10 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.93 | +159.07% | 2 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $39 | $16.51 | +136.22% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $4 | $5.72 | -30.07% | 13 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $13 → $19 | $13.38 | +42.00% | 8 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $3 | $1.14 | n/a | 17 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $11.29 | n/a | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $37.58 | n/a | 1 | Aug 8, 2023 |
Celldex Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $68
Current: $33.51
Upside: +102.92%
Kymera Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: $132 → $152
Current: $122.06
Upside: +24.53%
Roivant Sciences
Sep 17, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $38.22
Upside: +33.44%
Evommune
Sep 9, 2026
Reiterated: Buy
Price Target: $30
Current: $9.60
Upside: +212.50%
AnaptysBio
Sep 8, 2026
Rated: Hold
Price Target: n/a
Current: $53.92
Upside: -
Ascendis Pharma
Sep 1, 2026
Reiterated: Buy
Price Target: $328 → $326
Current: $237.57
Upside: +37.22%
Septerna
Aug 16, 2026
Reiterated: Buy
Price Target: $49 → $46
Current: $40.38
Upside: +13.92%
Alumis
Aug 13, 2026
Reiterated: Buy
Price Target: $44
Current: $8.11
Upside: +442.54%
Cullinan Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $28
Current: $21.67
Upside: +29.21%
Dianthus Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $133
Current: $98.35
Upside: +35.23%
Aug 13, 2026
Reiterated: Buy
Price Target: $40
Current: $16.76
Upside: +138.66%
Aug 13, 2026
Reiterated: Buy
Price Target: $123
Current: $91.97
Upside: +33.74%
Aug 13, 2026
Reiterated: Buy
Price Target: $40
Current: $22.12
Upside: +80.83%
Aug 11, 2026
Reiterated: Buy
Price Target: $49 → $57
Current: $37.29
Upside: +52.86%
Aug 9, 2026
Reiterated: Hold
Price Target: $62
Current: $60.28
Upside: +2.85%
Jul 28, 2026
Reiterated: Buy
Price Target: $1,255 → $1,282
Current: $963.79
Upside: +33.02%
Jul 6, 2026
Reiterated: Buy
Price Target: $5
Current: $1.69
Upside: +195.86%
Jun 29, 2026
Reiterated: Buy
Price Target: $150
Current: $94.55
Upside: +58.65%
May 28, 2026
Reiterated: Buy
Price Target: $5
Current: $1.93
Upside: +159.07%
May 15, 2026
Reiterated: Buy
Price Target: $36 → $39
Current: $16.51
Upside: +136.22%
May 8, 2026
Reiterated: Hold
Price Target: $2 → $4
Current: $5.72
Upside: -30.07%
Mar 1, 2026
Reiterated: Hold
Price Target: $13 → $19
Current: $13.38
Upside: +42.00%
Mar 3, 2025
Downgraded: Hold
Price Target: $32 → $3
Current: $1.14
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $23
Current: $11.29
Upside: n/a
Aug 8, 2023
Initiated Coverage: Buy
Price Target: $34
Current: $37.58
Upside: n/a